— Data Presented at 59th American Society of Hematology Annual Meeting & Exposition — SEATTLE, December 9, 2017 – Alpine…
Read More
— Data Presented at 2017 San Antonio Breast Cancer Symposium –– SEATTLE, December 6, 2017 – Alpine Immune Sciences, Inc….
New preclinical data to be presented at multiple upcoming scientific meetings Strong balance sheet with $87.2 million in cash, cash…
— Company’s vIgD Platform Well Positioned to Realize Next Generation Immuno-Oncology Therapeutics — SEATTLE, November 10, 2017 – Alpine Immune…
–Poster to be Presented at 2017 ACR/ARHP Annual Meeting– SEATTLE, November 6, 2017 – Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a…
SEATTLE, WA – October, 23, 2017— Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for…
SEATTLE, WA — (BUSINESS WIRE)– October 16, 2017– Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing…
Alpine Immune Sciences Announces Poster Presentation at 2017 ACR/ARHP Annual Meeting SEATTLE, WA–(BUSINESS WIRE)—September 20, 2017– Alpine Immune Sciences, Inc….
Alpine Immune Sciences to Present at Ladenburg Thalmann 2017 Healthcare Conference SEATTLE, WA –September 13, 2017– Alpine Immune Sciences, Inc….
Boulder, CO, July 20, 2017 – Nivalis Therapeutics, Inc. (Nivalis) (Nasdaq:NVLS) announced today that, based upon the final vote count certified by the independent inspector of elections for the special...
Read More